Healthcare News

Ligand to Participate in September Investor Conferences

U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection  Tuebingen, Germany, August 26, 2026 – HepaRegeniX GmbH...

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with...

Selskabsmeddelelse 21/2026                                                                   26 august 2026                                                               BESTYRELSESMEDLEMMERS,...

Corline Biomedical AB (”Corline”) publicerar härmed delårsrapporten för perioden januari till juni 2026. Nedan följer en kort sammanfattning av delårsrapporten. Fullständig rapport finns tillgänglig...

Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development...

Corline Biomedical AB intensifierar sin kommersiella satsning på den amerikanska marknaden för att ta tillvara det momentum som skapats efter FDA-godkännandet av Kardiums Globe® Pulsed Field System....

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...

FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing...

JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and...